Report Overview

The UK Rett Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Rett syndrome is a rare genetic neurological disorder that is more common among girls and leads to severe impairment affecting their ability to speak, walk and eat. Rett syndrome is recognized in children between 6-18 months caused by mutations on the X-chromosome over a gene called MECP2. Rett syndrome can cause a wide range of disabilities from mild to severe. Common symptoms of Rett syndrome include slowed growth, unusual eye movements, agitation and irritability, problems with hand movements, poor language skills, muscles and coordination problems, and trouble with breathing.

Health care professionals diagnosed Rett syndrome on the basis of MECP2 mutation. It is a rare condition so doctors also diagnosed other conditions such as prenatal brain disorder, autism spectrum disorder, metabolic disorder, and cerebral palsy to confirm Rett syndrome.

As per one of the studies conducted, more than 1500 people with Rett syndrome have been diagnosed in the UK. Moreover, the prevalence of Rett syndrome in females is around 1;10,000 while the prevalence of Rett syndrome in males is around 1:40,000.

Market Growth Drivers

The rise in the female population, expenditure on public healthcare programs and rising healthcare spending, availability of development of new drugs, and use of advanced technologies drive the Rett syndrome market growth. Increasing incidence and prevalence of Rett syndrome also anticipated enhancing the market growth.

However, increased focus on gene therapy treatment also boosts up the Rett syndrome market growth. It is expected to account for the largest market share over the forecast period for the Rett syndrome treatment market due to better healthcare infrastructure, rising economic growth, and an increase in the private healthcare sector.

Market Restraints

However, the high cost of treatment and rising R&D expenditure for the treatment of Rett syndrome may hamper the Rett syndrome market growth. Under-enrolment of participants in trials is one of the biggest challenges for researchers and trial sponsors, and it can slow the development of a potential treatment.